Miguel Martín

3.1k total citations · 2 hit papers
15 papers, 1.9k citations indexed

About

Miguel Martín is a scholar working on Oncology, Genetics and Molecular Biology. According to data from OpenAlex, Miguel Martín has authored 15 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 10 papers in Genetics and 7 papers in Molecular Biology. Recurrent topics in Miguel Martín's work include PARP inhibition in cancer therapy (12 papers), BRCA gene mutations in cancer (10 papers) and DNA Repair Mechanisms (7 papers). Miguel Martín is often cited by papers focused on PARP inhibition in cancer therapy (12 papers), BRCA gene mutations in cancer (10 papers) and DNA Repair Mechanisms (7 papers). Miguel Martín collaborates with scholars based in Spain, United States and South Korea. Miguel Martín's co-authors include Jennifer K. Litton, W. Eiermann, Henri Roché, Johannes Ettl, Rinat Yerushalmi, Anthony Gonçalvès, Sara A. Hurvitz, Joanne L. Blum, Young‐Hyuck Im and Lida A. Mina and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Cancer Research.

In The Last Decade

Miguel Martín

15 papers receiving 1.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation

2018 1.4k citations Jennifer K. Litton, Hope S. Rugo et al. New England Journal of Medicine profile →
Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial

2020 252 citations Jennifer K. Litton, Sara A. Hurvitz et al. Annals of Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Miguel Martín Spain	8	1.5k	753	657	585	511	15	1.9k
Sarah Runswick United Kingdom	9	2.3k 1.5×	1.3k 1.7×	932 1.4×	820 1.4×	869 1.7×	18	3.0k
Jacqui Rowbottom United Kingdom	10	1.2k 0.8×	567 0.8×	791 1.2×	215 0.4×	321 0.6×	14	1.6k
Patrick G. Pilié United States	13	1.1k 0.7×	1.1k 1.4×	407 0.6×	135 0.2×	342 0.7×	43	1.8k
Niklas Loman Sweden	2	1.0k 0.7×	774 1.0×	238 0.4×	463 0.8×	323 0.6×	5	1.3k
Lynda Grinsted United Kingdom	11	850 0.6×	703 0.9×	730 1.1×	171 0.3×	376 0.7×	19	1.4k
Marina Parton United Kingdom	18	955 0.6×	577 0.8×	298 0.5×	164 0.3×	743 1.5×	49	1.6k
Wassim Abida United States	21	785 0.5×	1.0k 1.3×	945 1.4×	131 0.2×	583 1.1×	93	1.9k
Maria Orr United Kingdom	12	1.3k 0.9×	794 1.1×	273 0.4×	473 0.8×	363 0.7×	16	1.8k
Shaveta Vinayak United States	15	790 0.5×	429 0.6×	239 0.4×	160 0.3×	351 0.7×	45	1.2k
Aglaya G. Iyevleva Russia	22	588 0.4×	689 0.9×	473 0.7×	452 0.8×	482 0.9×	78	1.5k

Countries citing papers authored by Miguel Martín

Since Specialization

Citations

This map shows the geographic impact of Miguel Martín's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Miguel Martín with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Miguel Martín more than expected).

Fields of papers citing papers by Miguel Martín

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Miguel Martín. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Miguel Martín. The network helps show where Miguel Martín may publish in the future.

Co-authorship network of co-authors of Miguel Martín

This figure shows the co-authorship network connecting the top 25 collaborators of Miguel Martín. A scholar is included among the top collaborators of Miguel Martín based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Miguel Martín. Miguel Martín is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

Litton, Jennifer K., Sara A. Hurvitz, Lida A. Mina, et al.. (2020). Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial. Annals of Oncology. 31(11). 1526–1535. 252 indexed citations breakdown →

García‐Alfonso, Pilar, et al.. (2020). Prognostic value of molecular biomarkers in patients with metastatic colorectal cancer: a real-world study. Clinical & Translational Oncology. 23(1). 122–129. 3 indexed citations

Calles, Antonio, Javier Soto, Victoria Tirado, et al.. (2020). Outcomes of COVID-19 in Patients With Lung Cancer Treated in a Tertiary Hospital in Madrid. Frontiers in Oncology. 10. 1777–1777. 25 indexed citations

Litton, Jennifer K., Douglas Laird, Hope S. Rugo, et al.. (2020). Exploring impact of mutations in non-BRCA DNA damage response (DDR) and non-DDR genes on efficacy in phase III EMBRACA study of talazoparib (TALA) in patients (pts) with germline BRCA1/2 mutated (gBRCAm) HER2-negative (HER2-) advanced breast cancer (ABC).. Journal of Clinical Oncology. 38(15_suppl). 1018–1018. 1 indexed citations

Litton, Jennifer K., Sara A. Hurvitz, Lida A. Mina, et al.. (2020). Abstract CT071: Talazoparib (TALA) in germline BRCA1/2 (gBRCA1/2)-mutated human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer (ABC): Final overall survival (OS) results from randomized Phase 3 EMBRACA trial. Cancer Research. 80(16_Supplement). CT071–CT071. 7 indexed citations

Jerez, Yolanda, et al.. (2019). Poly (ADP-ribose) Polymerase Inhibition in Patients with Breast Cancer and BRCA 1 and 2 Mutations. Drugs. 80(2). 131–146. 12 indexed citations

Ettl, Johannes, Sara A. Hurvitz, Hope S. Rugo, et al.. (2019). Outcomes of talazoparib (TALA) versus physician's choice of chemotherapy (PCT) in patients (pts) with advanced breast cancer (ABC) and a germline BRCA (gBRCA) mutation by line of chemotherapy (CT) in the EMBRACA trial.. Journal of Clinical Oncology. 37(15_suppl). 1071–1071. 2 indexed citations

Litton, Jennifer K., HS Rugo, Johannes Ettl, et al.. (2018). Abstract GS6-07: EMBRACA: A phase 3 trial comparing talazoparib, an oral PARP inhibitor, to physician's choice of therapy in patients with advanced breast cancer and a germline BRCA mutation. Cancer Research. 78(4_Supplement). GS6–7. 40 indexed citations

Litton, Jennifer K., Hope S. Rugo, Johannes Ettl, et al.. (2018). Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation. New England Journal of Medicine. 379(8). 753–763. 1401 indexed citations breakdown →

10.

Ettl, Johannes, Ruben G.W. Quek, Ki Hoon Lee, et al.. (2018). Quality of life with talazoparib versus physician’s choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation: patient-reported outcomes from the EMBRACA phase III trial. Annals of Oncology. 29(9). 1939–1947. 106 indexed citations

11.

Gonçalvès, Anthony, W. Eiermann, Hope S. Rugo, et al.. (2018). EMBRACA: Efficacy and safety in comparing talazoparib (TALA) with physician's choice of therapy (PCT) in patients (pts) with advanced breast cancer (aBC) and a germline BRCA mutation (gBRCAm); BRCA1/BRCA2 subgroup analysis. Annals of Oncology. 29. viii96–viii97. 3 indexed citations

12.

Litton, Jennifer K., Johannes Ettl, SA Hurvitz, et al.. (2017). Abstract OT2-01-13: A phase 3, open-label, randomized, 2-arm international study of the oral dual PARP inhibitor talazoparib in germline BRCA mutation subjects with locally advanced and/or metastatic breast cancer (EMBRACA). Cancer Research. 77(4_Supplement). OT2–1. 1 indexed citations

13.

Litton, Jennifer K., Joanne L. Blum, W. Eiermann, et al.. (2015). Abstract OT1-1-12: A phase 3, open-label, randomized, parallel, 2-arm multi-center study of the oral PARP inhibitor BMN 673 versus physician's choice in germline BRCA mutation subjects with locally advanced and/or metastatic breast cancer (EMBRACA study). Cancer Research. 75(9_Supplement). OT1–1. 2 indexed citations

14.

Litton, Jennifer K., Joanne L. Blum, Young‐Hyuck Im, et al.. (2015). A phase 3, open-label, randomized, parallel, 2-arm international study of the oral PARP inhibitor talazoparib (BMN 673) in BRCA mutation subjects with locally advanced and/or metastatic breast cancer (EMBRACA).. Journal of Clinical Oncology. 33(15_suppl). TPS1107–TPS1107. 11 indexed citations

15.

Martín, Miguel, et al.. (1992). Intravenous and Oral Magnesium Supplementations in the Prophylaxis of Cisplatin-Induced Hypomagnesemia. American Journal of Clinical Oncology. 15(4). 348–351. 39 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact